Replies to post #33235 on Applied DNA Sciences Inc (APDN)

[mcsharkey]

Yeah Pasta, thinking I found a clause ceasing and desisting dilutive practices henceforth and forever (naah, not forever) I'll post here. In the meantime.

What kind of movie would most likely perk you up? War torn savagery, mythological fantasy, chick flick tear jerker, Ballywood musical?:)

Playing now Brother. Here's what I found, From NOTE L, Subsequent Events, sheet F-67 on the HTML file. If you have and Acrobat file of the prospectus, page 153 of 168. Section prefaces this with all the warrant and option issues done to date.

I got more questions, no answers.

GLTU, enjoy the movies,
GLTA
Mike Sharkey

Crede has the right to participate in other equity or equity-linked financings completed by the Company for a period of 180 days from the later of the Initial Closing or the date the registration statement goes effective.
In addition, the Company has agreed not to issue additional Common Stock or securities convertible into Common Stock at a price below $0.186 per share or the market price of the Common Stock on the date the registration statement is declared effective, for a period of 180 days from the effective date of the registration statement, except for issuances:

(i) pursuant to acquisitions, joint ventures, license arrangements, leasing arrangements and other similar arrangements,

(ii) to employees, consultants, directors and officers approved by the Board or pursuant to a plan approved by the Board,

(iii) pursuant to one or more contracts entered into by the Company with third parties which would result in revenues to the Company during a threemonth period equal to an annual run rate of $15 Million in revenues and

(iv) pursuant to a contract entered into by the Company with a third party which would reasonably be expected to result in more than $3 Million in annual receivables.

Until one year after the Second Closing, the Company is prohibited from entering into any transaction to:

(i) sell any convertible securities at a conversion rate or other price that is generally based on and/or varies with the trading prices of the Company’s Common Stock at any time after the initial issuance of such convertible securities or

(ii) sell securities at a future determined price, including, without limitation, an “equity line of credit” or an “at the market offering.”